BioNTech is stepping on AstraZeneca and Daiichi Sankyo’s turf with the launch of a Phase III trial for its antibody-drug conjugate aiming at a subset of breast cancer patients who historically have had few treatment options.
The German biotech licensed DB-1303, or BNT323, in April as part of a deal where it paid China’s DualityBio $170 million upfront. Like other ADCs, it consists of an antibody that homes in on the target (in this case, HER2), a payload to kill the cancer cells and a linker to connect the two. Specifically, it utilizes a topoisomerase-1 inhibitor as the cancer-killing payload.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.